112 results about "CLAVULANATE POTASSIUM" patented technology

The invention discloses a preparation method of amoxicillin and clavulanate potassium tablets, comprising the following steps: (a) weighing the following main and auxiliary materials: 120-135 parts of amoxicillin, 40-45 parts of clavulanate potassium, 27-32 parts of microcrystalline cellulose, 1-3 parts of croscarmellose sodium (ADS), 1-3 parts of superfine silica powder and 2-4 parts of magnesium stearate; (b) after pelletizing amoxicillin, mixing the pelletized amoxicillin with clavulanate potassium according to the mass ratio of 4:1 to form the main materials; (c) uniformly mixing the auxiliary materials including superfine silica powder, ADS and microcrystalline cellulose by the method of increment by equal quantity and throwing the main materials and the auxiliary materials into a mixer by the method of increment by equal quantity to be mixed for 36-70min; and (d) tabletting the mixed powder. The products prepared by the method have bright, clean and beautiful appearances and stable content and dissolution.

The invention provides a beta-cyclodextrin / amoxicillin inclusion compound medicinal composition which comprises amoxicillin and beta cyclodextrin by the weight ratio of 1:2.5-1:5. In a preferred embodiment, the composition also comprises clavulanate potassium, wherein the mass ratio of amoxicillin and clavulanate potassium is 14:1-2:1, the supplementary materials are selected from crystalline cellulose, maize starch, citric acid, talcum powder, sodium carboxymethylstarch, stearic acid, calcium stearate, magnesium stearate, amylopectin, lactose, mannitol, crosslinked povidone, talcum powder, polyethylene glycol 4000, and low substituted methylcellulose propylene glycol ether. The invention also discloses the preparing process.

The invention discloses a beta- lactamase suppressing antibacterial compound drugs, which comprises ceftizoxime, or cefodizime and beta-lactam enzyme inhibitor by the active acid weight ratio of 1-10:10-1, which are in the forms of alkali metal salts or free acid and assisting solvents, the beta-lactam enzyme inhibitor can be Tazobactam, or clavulanic acid, or tapazole or their derivatives.

The invention provides a novel high-efficiency liquid chromatography (HPLC) method capable of synchronously detecting the contents of two single ingredients and relevant impurities in injection use compound amoxicillin sodium and clavulanate potassium. Compared with the existing detection method, the invention has higher precision on the 7/1 compound preparation with relatively low clavulanic acid content, and has better separation degree on the injection preparation with higher purity requirement, in addition, the two ingredients of the amoxicillin and the clavulanic acid can not be mutually interfered or influenced in the detection process. The method has the advantages of simple operation, easy implementation, strong specificity, high sensitivity, large linear range, good stability and good repetitiveness, and can be used for detecting compound sterile injection preparations and raw materials.

The invention provides a liposome injection of a pharmaceutical composition of amoxicillin sodium and clavulanate potassium, which consists of amoxicillin sodium, clavulanate potassium, a liposome carrier, a lyoprotectant and a freely optional antioxidant, wherein the liposome carrier is egg yolk phosphatidylinositol and sodium taurocholate. The liposome injection has good preparation stability, liposome can avoid the fracture due to dehydration, fusion, ice crystal generation and the like during the freeze-drying process, and the liposome can still keep the good encapsulation rate after hydration and redissolution.

The invention belongs to the technical field of medical technology, and particularly relates to an amoxicillin and clavulanate potassium injection and a preparation method of the amoxicillin and clavulanate potassium injection. The amoxicillin and clavulanate potassium injection includes amoxicillin sodium, potassium clavulanate and a pH regulator. The preparation method comprises the steps of crushing and mixing the amoxicillin sodium, the potassium clavulanate and the pH regulator uniformly through air flows according to certain proportion, then respectively packaging the mixture into penicillin bottles, controlling the water content to be 0.5%, filling nitrogen for protection, plugging, rolling a cover and finally packaging. According to the invention, the obtained product is stable in quality, the problems of the color changing and the deterioration caused by the easy oxidization of the similar products can be solved, the product quality is improved, and high economical benefits are obtained.

The invention discloses a slow release medicament three-layer tablet which comprises Amoxicillin hydrate, clavulanate potassium and pharmaceutically acceptable excipient or carrier, the layer 1 is a rapid release layer comprising Amoxicillin hydrate and clavulanate potassium, the layer 2 is a rapid release layer comprising a portion of Amoxicillin hydrate, the layer 3 is a rapid release layer comprising rest portions of Amoxicillin hydrate, the slow release layer contains not only common medicinal adjuvant, but also slow release material of hydroxy propyl methyl cellulose E30.

The invention discloses a method for simultaneously measuring the plasma concentration of amoxicillin and clavulanate potassium. The method comprises the steps of depositing proteins of a human plasma sample with methyl alcohol by taking acetaminophen as an interior label, then performing high-speed concentric sample injection, and obtaining the lowest detection concentration of amoxicillin and clavulanate potassium by taking C18 as a chromatographic column and acetonitrile-0.05mmol/L phosphate buffering solution as a flowing phase under the condition that the ultraviolet detection wavelength is 220nm. The method is simple, accurate, sensitive, high in specificity and high in reproducibility and can be used as a plasma concentration measurement method for the biological availability and the bioequivalence study of amoxicillin and clavulanate potassium.

The invention discloses an amoxicillin/clavulanate potassium enteric-coated preparation composition and a preparation method thereof. The preparation composition is mainly prepared from amoxicillin, clavulanate potassium and an appropriate auxiliary material. Compared with the common amoxicillin/clavulanate potassium preparation, the amoxicillin/clavulanate potassium enteric-coated preparation provided by the invention has the advantages of less irritation to the stomach so as to reduce adverse reaction, and the like. The amoxicillin/clavulanate potassium enteric-coated preparation composition is particularly suitable for patients with stomach upset. The invention provides a novel formulation which has higher safety and better curative effect compared with those of the conventional amoxicillin/clavulanate potassium related preparations; and the preparation process has the advantages of high quality controllability and stability.

The invention relates to a compound amoxicillin and clavulanate potassium tablet and a preparation method thereof. The tablet consists of the following components in percentage by weight: 15 to 30 percent of amoxicillin, 5 to 15 percent of a clavulanate potassium mixture, 30 to 65 percent of a filler, 1.5 to 8 percent of crosslinked povidone, 0.6 to 3 percent of povidone K30, 1 to 3 percent of silica and 1 to 5 percent of glyceryl behenate. The preparation method comprises the following steps: adding the amoxicillin, the filler and the crosslinked povidone into a pelletizer, mixing and adding an adhesive in a mixing process; and adding the prepared amoxicillin granules and clavulanate potassium mixture, the silica and the glyceryl behenate into a mixing machine, mixing, discharging and tabletting. Although the compound amoxicillin and clavulanate potassium tablet adopts a half-wet method to pelletize, the clavulanate potassium is unlikely to degrade, so that the stability of a medicine is guaranteed effectively.

The invention provides a stable amoxicillin and clavulanate potassium sustained release preparation, which is composed of a rapid-release layer and a slow-release layer. The weight ratio of amoxicillin to clavulanate potassium is 1000:62.5, the proportion of amoxicillin in the rapid-release layer and the slow-release layer is 1:1, all of clavulanate potassium is placed in the rapid-release layer, wherein the pharmaceutic auxiliary material comprises the following ingredients by weight: the ratio of amoxicillin to slow release material to lubricant to adhesive in the slow release layer is 500:140-150:5-10:16:23, the ratio of amoxicillin to clavulanate potassium to disintegrating agent to lubricant to coating powder in the rapid-release layer is 62.5:30-60:6-10:40-80. The amoxicillin and clavulanate potassium sustained release preparation has the characteristics of good stability, high curative effect, low side-effect incidence rate and reduced drug usage frequency.

The invention belongs to the field of chemosynthesis, and particularly relates to a preparation method of amoxicillin and clavulanate potassium tablets. The preparation method comprises the following steps: mixing major ingredients, mixing minor ingredients, pressing particles, sieving, repeatedly pressing particles, tabletting, coating and the like. The preparation method enhances the control to the pelletizing and tabletting processes of the amoxicillin and clavulanate potassium tablets, introduces a novel coating technology to overcome the defects of poor humidity controllability of the amoxicillin and clavulanate potassium tablets and product instability, ensures the quality of drugs, and improves the production efficiency; the steps of crushing, sieving and selecting fine powders to be pressed into particles are repeated.

The invention provides an injection-use pharmaceutical composition comprising cefmetazole sodium and clavulanate potassium, and the pharmaceutical composition has a cooperatively antibacterial effect. The pharmaceutical composition comprises the following ingredients: in parts by weight, 1-4 parts of the cefmetazole sodium; 1-2 parts of the clavulanate potassium; 2-6 parts of polyalkylcyanoacrylate; 0.2-0.5 parts of L-arginine; 0.5-1 parts of PVP; 0.5-1 parts of mannitol; 0.5-1 parts of glycine; 1-2 parts of a tween. The pharmaceutical composition has the advantages of high stability, good redissolubility, simple preparation processes, a good inhibitory effect on ESBLs-producing escherichiacoli, klebsiellapeumoniae, and proteusmirabilis, and a definite curative effect, can reduce the dosage of a single prescription preparation and shorten the treatment cycle, and has broad market prospects.

The invention relates to amoxicillin and clavulanate potassium preparations and preparation method thereof. Amoxicillin and clavulanate potassium can be prepared into two preparations including that amoxicillin and clavulanate potassium are mixed and dissolved with a certain amount of water-soluble matrixes and then prepared into dropping pills through dropping pill preparation technology; or, amoxicillin and additives are micro-ground and uniformly mixed, then clavulanate potassium is dissolved in a certain amount of water into binding agent, and through spraying granulation, the materials are prepared into granules. The amoxicillin and clavulanate potassium preparations prepared through the methods above have the advantages of being simple in production, high in bioavailability, rapid inabsorption and effects and the like.

The invention discloses electrolyte for a secondary battery. The electrolyte is prepared from the following raw materials including acid sulfate, solvents and additives, wherein the acid sulfate is prepared by mixing sodium hydrogensulfate and potassium hydrogensulfate; the solvents are one kind of materials or a composition of a plurality of kinds of materials from water, maleic acid, tetrahydrofurfuryl alcohol, a boric acid solution, porphyrin, acrylic acid, dibutyl carbonate, isoamyl acetate, povidon iodine, triethyl phosphate and water glass; the additives are prepared from the following raw materials including lithium borate oxalate, glycol sulfite, sodium chromate, carboxymethyl chitosan, sodium selenite and potassium clavulanate. The electrolyte for the secondary battery has the advantages that each performance completely conforms to the national standard; the defects of long formation time, non-thorough formation and poor uniformity in the ordinary lead acid storage battery canbe successfully overcome; the stability of the battery is greatly improved.

The invention provides a method for measuring amoxicillin content of amoxicilin sodium and clavulanate potassium. The interference of clavulanate potassium can be eliminated in an environment with certain pH values and in a certain wavelength range, and the measurement result can be accurate; and the method is simple and convenient and can provide support for controlling the acceptable quality of the amoxicilin sodium and clavulanate potassium in production.

The invention discloses an amoxicillin and clavulanate potassium dispersible tablet applied to the field of a preparation of the amoxicillin and clavulanate potassium dispersible tablet. The dispersible tablet is prepared from the following components: amoxicillin trihydrate, clavulanate potassium, microcrystalline cellulose, a disintegrant, diatomite, a sweetener and an aromatic, wherein the disintegrant is selected from one of croscarmellose sodium, carboxymethyl starch sodium and polyvinylpolypyrrolidone; the disintegrant is preferably selected from croscarmellose sodium; the sweetener is selected from one of aspartame and sucralose; the aromatic is selected from one of a blueberry flavor and a lemon essence; the sweetener is preferably selected from sucralose; the aromatic is preferably selected from the blueberry flavor; the weight ratio of amoxicillin trihydrate to clavulanate potassium in the dispersible tablet is 4:1 based on amoxicillin and clavulanate; the dispersible tablet is prepared from powder by a direct compression method. The amoxicillin and clavulanate potassium dispersible tablet is rapid to disintegrate, still can be rapidly disintegrated at low water temperature, and is good in stability, good in mouthfeel, simple in prescription, good in mobility of mixed powder in the prescription, and not sticking in the tabletting process.

The invention discloses a medicinal composition, which comprises the following components in parts by weight: 5 to 15 parts of amoxicillin, 1 to 5 parts of clavulanate potassium, and 1 to 5 parts of ambroxol hydrochloride. The invention discloses an application of the medicinal composition in preparing medicaments for treating animal respiratory infectious diseases, in particular for preparing porcine infectious pleuropneumonia and haemophilusparasuis. The invention also discloses a preparation method of compound amoxicillin soluble powder. The compound amoxicillin soluble powder comprises the following components in parts by weight: 5 to 15 parts of amoxicillin, 1 to 5 parts of clavulanate potassium, 1 to 5 parts of ambroxol hydrochloride, and 75 to 93 parts of glucosum anhydricum. The raw materials are uniformly mixed according to an equivalent incremental principle to obtain the compound amoxicillin soluble powder. The medicinal composition disclosed by the invention is reasonable and scientific in prescription, the bioavailability of amoxicillin can be increased compared with an amoxicillin preparation, the drug resistance is reduced, and the curative effect is improved.

The invention relates to a compound amoxicillin breast injectant prescription and a preparation method thereof. The compound amoxicillin breast injectant prescription comprises a suspending aid, an antioxidant and a solid dispersion carrier which are prepared through a special process to obtain white to off-white oily suspension. The compound amoxicillin breast injectant prescription disclosed by the invention has the advantages of simple preparation process, stable content, easy injection and the like. The composition disclosed by the invention is compounded from amoxicillin, clavulanate potassium and prednisolone; compared with other amoxicillin patent preparations, the composition has drug-tolerant bacteria for penicillins, and also has a high inhibition effect on the chromosome exzymes generated by klebsiella peneumoniae, bacillus proteus vulgaris and bacteroides fragilis; prednisolone has anti-inflammatory and antiallergic functions, and has a synergistic effect on bacterial infection and allergic inflammation.